PMID- 23224580
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130129
LR  - 20220801
IS  - 1523-3847 (Print)
IS  - 1523-3847 (Linking)
VI  - 15
IP  - 1
DP  - 2013 Feb
TI  - The immune reconstitution inflammatory syndrome: a clinical update.
PG  - 39-45
LID - 10.1007/s11908-012-0308-y [doi]
AB  - The immune reconstitution inflammatory syndrome (IRIS) is a well-described 
      phenomenon in HIV-infected patients following initiation of antiretroviral 
      therapy and can lead to significant morbidity and mortality in some patients. 
      Risk for IRIS is enhanced in those with low CD4 counts and preexisting 
      opportunistic infections. The development of pathogen-specific definitions of 
      IRIS has aided classification of patients and has facilitated research. Newer 
      data on optimal timing of ART initiation, with additional data in the setting of 
      tuberculosis and cryptococcal meningitis, will help guide strategies to decrease 
      the risk of IRIS but must balance the risks of HIV disease progression. Managing 
      patients with IRIS can be challenging. Treatment options include 
      pathogen-specific therapy, antiinflammatory therapies, and other novel 
      approaches.
FAU - Armstrong, Wendy S
AU  - Armstrong WS
AD  - Division of Infectious Disease, Emory University School of Medicine, 341 Ponce de 
      Leon Ave, Atlanta, GA, 30308, USA, wsarmst@emory.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Infect Dis Rep
JT  - Current infectious disease reports
JID - 100888983
EDAT- 2012/12/12 06:00
MHDA- 2012/12/12 06:01
CRDT- 2012/12/11 06:00
PHST- 2012/12/11 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2012/12/12 06:01 [medline]
AID - 10.1007/s11908-012-0308-y [doi]
PST - ppublish
SO  - Curr Infect Dis Rep. 2013 Feb;15(1):39-45. doi: 10.1007/s11908-012-0308-y.